European neurological review最新文献_第7页

Parkinson’s Disease Psychosis – Prevalence Patterns Across the EU-5 帕金森氏症精神病-在欧盟五国的流行模式

European neurological review Pub Date : 2017-01-01 DOI: 10.17925/ENR.2017.12.02.87

K. Cook, R. Suresh, K. Lou, J. Kesslak, D. Fredericks

{"title":"Parkinson’s Disease Psychosis – Prevalence Patterns Across the EU-5","authors":"K. Cook, R. Suresh, K. Lou, J. Kesslak, D. Fredericks","doi":"10.17925/ENR.2017.12.02.87","DOIUrl":"https://doi.org/10.17925/ENR.2017.12.02.87","url":null,"abstract":"P arkinson’s disease psychosis (PDP) is a clinical condition that affects patients diagnosed with Parkinson’s disease (PD) and has a spectrum of neuropsychiatric symptoms distinct from the hallmark motor symptoms. Although prior studies have reported on the prevalence of PDP in select European nations, variations in study design complicate study-to-study comparisons. In this study, we surveyed 1,667 medical practitioners across France, Germany, Italy, Spain, and the UK (collectively, the EU-5) to estimate the prevalence of PDP or symptoms of psychosis among patients with PD. Analysis of the survey data suggest approximately 29% of the general PD population in the EU-5 exhibit signs of PDP. Among the PD population, country-specific rates of PDP are estimated at 30% in France, 27% in Germany, 34% in Italy, 30% in Spain and 21% in the UK. These rates appear in line with those reported in prior country-specific studies. Results from the subset of 437 neurologists who proceeded to take the full survey suggest the symptoms of PDP are disruptive to patients or their respective caregivers in approximately 53% of cases. These results provide a resource that enables cross-country comparison of PDP rates across these major European nations.","PeriodicalId":12047,"journal":{"name":"European neurological review","volume":"12 1","pages":"87"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67592436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Cerebrovascular Lesions in Pick Complex Diseases – A Neuropathological Study with a 7.0-Tesla Magnetic Resonance Imaging Study Pick复杂疾病的脑血管病变- 7.0特斯拉磁共振成像研究的神经病理学研究

European neurological review Pub Date : 2017-01-01 DOI: 10.17925/ENR.2017.12.02.84

J. Reuck

引用次数: 4

Optimizing the use of outcome measures in chronic inflammatory demyelinating polyneuropathy 优化慢性炎症性脱髓鞘性多神经病变预后指标的使用

European neurological review Pub Date : 2017-01-01 DOI: 10.17925/USN.2017.13.01.26

Jeffrey A. Allen, D. Gelinas, R. Lewis, R. Nowak, G. Wolfe

引用次数: 9

Safinamide - a unique treatment targeting both dopaminergic and non-dopaminergic systems 沙芬胺-一种针对多巴胺能和非多巴胺能系统的独特治疗方法

European neurological review Pub Date : 2016-10-04 DOI: 10.17925/ENR.2016.11.02.101

K. Bojarski, Jaume

引用次数: 2

Different Presentations of Myelopathy—A Case Series 脊髓病的不同表现- a病例系列

European neurological review Pub Date : 2016-03-01 DOI: 10.17925/USN.2016.12.01.22

Krishna Pokala, D. Girard, S. Beydoun

引用次数: 2

The Role of Noninvasive Neuromodulation in Migraine Management 无创神经调节在偏头痛治疗中的作用

European neurological review Pub Date : 2016-01-01 DOI: 10.17925/ENR.2016.11.02.106

F. Puledda, P. Goadsby

引用次数: 2

Spastic Paresis and Rehabilitation – The Patient Journey 痉挛性麻痹和康复-病人的旅程

European neurological review Pub Date : 2016-01-01 DOI: 10.17925/ENR.2016.11.02.87

D. Bowers, K. Fheodoroff, P. Khan, J. Harriss, K. Dashtipour, L. Bahroo, Michael Y. Lee, D. Zakharov, J. Balcaitiene, V. Evidente

引用次数: 2

Improving Patient Outcomes in Preventing Atrial Fibrillation-related Stroke with Non-Vitamin K Antagonist Oral Anticoagulants 非维生素K拮抗剂口服抗凝剂预防房颤相关卒中改善患者预后

European neurological review Pub Date : 2016-01-01 DOI: 10.17925/ENR.2016.11.01.1a

P. Kelly, C. Molina, C. Ruff, R. Veltkamp

{"title":"Improving Patient Outcomes in Preventing Atrial Fibrillation-related Stroke with Non-Vitamin K Antagonist Oral Anticoagulants","authors":"P. Kelly, C. Molina, C. Ruff, R. Veltkamp","doi":"10.17925/ENR.2016.11.01.1a","DOIUrl":"https://doi.org/10.17925/ENR.2016.11.01.1a","url":null,"abstract":"The rising incidence of atrial fibrillation (AF) is increasingly resulting in a substantial worldwide increase in AF-related stroke, particularly in elderly patients and this is creating an increasingly serious healthcare burden. Guidelines recommend the use of AF-related stroke prophylaxis but adherence to these remains poor. Studies conducted in the 1990s showed that warfarin reduced the risk of AF-related stroke by an overall 64% compared with placebo. Subsequently, prophylactic treatment was further improved with the development of non-vitamin K antagonist oral anticoagulants (NOACs). More recently, a meta-analysis of four large clinical trials on NOACs (dabigatran, rivaroxaban, apixaban, and edoxaban) showed there was a relative risk reduction of 0.81 (p<0.0001) favouring NOAC treatment over warfarin for stroke or systemic embolic events in patients with AF. The largest trial of NOACs in AF-related stroke, to date, was the ENGAGE AF-TIMI 48 study (n=21,105) which showed that edoxaban was non-inferior to warfarin for ischaemic stroke reduction but significantly reduced bleeding and cardiovascular mortality. A recent subgroup analysis of this study showed that with edoxaban the incidences of intracranial haemorrhage (ICH) subtypes (all ICH, fatal ICH, fatal, subdural and epidural bleed) were significantly lower with 60 mg of edoxaban (p=0.013–<0.001). Edoxaban was also shown to be an effective option in patients with prior stroke. In addition, edoxaban was shown to reduce deaths due to fatal bleeds compared with warfarin. The results of current studies, especially the ENGAGE AF-TIMI 48 subgroup analysis therefore, show that the benefits of anticoagulation therapy in patients with AF substantially outweigh the risks.","PeriodicalId":12047,"journal":{"name":"European neurological review","volume":"700 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67591789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and Safety of Existing and Emerging Monoclonal Antibody Therapies for Multiple Sclerosis 现有和新兴单克隆抗体治疗多发性硬化症的疗效和安全性

European neurological review Pub Date : 2016-01-01 DOI: 10.17925/ENR.2016.11.02.96

G. Giovannoni

引用次数: 0

Evaluation and Treatment of Neurogenic Bowel Dysfunction – A Review 神经源性肠功能障碍的评估和治疗综述

European neurological review Pub Date : 2016-01-01 DOI: 10.17925/ENR.2016.11.02.109

L. Kumar, E. Athanasakos, A. Emmanuel

引用次数: 3